Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400537 | 0.98 | CXCR4 (0.66) | CXCR4POLBTLR8CYP2D6HTT | |
| SCHEMBL11718288 | 0.91 | CXCR4 (0.69) | CXCR4POLBTLR8CYP2D6HTT | |
| SCHEMBL10025495 | 0.90 | CXCR4 (0.71) | CXCR4POLBTLR8CYP2D6HTT | |
| SCHEMBL3599686 | 0.87 | LMNA (0.68) | CXCR4POLBTLR8CYP2D6HTT | |
| SCHEMBL823412 | 0.87 | POLB (0.63) | CXCR4POLBTLR8CYP2D6HTT | |
| SCHEMBL6199065 | 0.85 | CXCR4 (0.85) | CXCR4POLBTLR8CYP2D6HTT | |
| SCHEMBL23362149 | 0.83 | CXCR4 (0.57) | CXCR4POLBTLR8CYP2D6HTT | |
| SCHEMBL3757039 | 0.82 | LMNA (0.74) | POLBCYP2D6HTTALOX15MAPT | |
| SCHEMBL11712420 | 0.80 | CXCR4 (0.66) | CXCR4POLBTLR8CYP2D6HTT | |
| SCHEMBL6196399 | 0.79 | CXCR4 (1.00) | CXCR4POLBTLR8CYP2D6HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297038-A1 | Benzimidazole Derivatives And Their Use As Cooling Agents | GIVAUDAN S.A. (CH) | 2010-11-25 | — | — | US | claimed |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2015-05-07 | — | — | US | disclosed |
| US-20100297038-A1 | Benzimidazole Derivatives And Their Use As Cooling Agents | GIVAUDAN S.A. (CH) | 2010-11-25 | — | — | US | disclosed |
| EP-0571253-B1 | Benzimidazole derivatives with antidiabetic and antiplatelet aggregation activity | ADIR (FR) | 1998-11-04 | — | — | EP | disclosed |
| US-5639756-A | ANTIDIABETIC AGENTS | ADIR ET COMPAGNIE (FR) | 1997-06-17 | — | — | US | disclosed |
| US-5623073-A | ANTIDIABETIC AGENT | ADIR ET COMPAGNIE (FR) | 1997-04-22 | — | — | US | disclosed |
| EP-0571253-A1 | Benzimidazole derivatives with antidiabetic and antiplatelet aggregation activity | ADIR ET COMPAGNIE (FR) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | CXCR4 206/4885POLB 2512/4885TLR8 232/4885 |
| US-20100297038-A1 | Benzimidazole Derivatives And Their Use As Cooling Agents | OR10J3, H1-3, ORC3 | CXCR4 611/4885POLB 2220/4885TLR8 3628/4885 |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | CXCR4 195/4885POLB 2506/4885TLR8 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.